Prostate Cancer Clinical Trial
— VIOLETTEOfficial title:
Prospective Multicenter Trial Assessing the Efficacy of a Novel 3D Cartography-based Targeted Focal Microwave Therapy in Men With Localized Intermediate-risk Prostate Cancer
Multicenter, prospective, European, single-arm, open-label, 12-month follow-up clinical trial. The purpose of this study is to evaluate the efficacy of a 3D cartography-based targeted microwave ablation for the treatment of the index lesion in patients with intermediate risk prostate cancer.
Status | Recruiting |
Enrollment | 65 |
Est. completion date | May 2023 |
Est. primary completion date | May 2023 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 45 Years to 76 Years |
Eligibility | Inclusion Criteria: - Patient aged from 45 to 76 years old - Life expectancy >10 years at the inclusion time - Patient diagnosed with an intermediate-risk prostate cancer, defined by: - A T1c or T2a clinical stage - A unique cancer focus of Gleason (3+4) (Grade Group 2) - A PSA level <20 ng/mL - Cancer focus identified on a multiparametric MRI of the prostate no more than 3 months before inclusion - Confirmation of the suspicion of cancer identified on the MRI with transrectal or transperineal targeted and systematic biopsies performed with the KOELIS TRINITY system (no more than 3 months before inclusion) - Patient suitable for IV sedation or general anesthesia and focal microwave ablation - No debilitating medical or psychiatric illness that would preclude giving informed consent or receiving optimal treatment and follow-up - Known coagulopathy or bleeding disorders are controlled - Free, informed and written consent, dated and signed before the enrollment and before any exam required by the trial - Patient affiliated to social security regimen or beneficiary of such regimen for local regions Exclusion Criteria: - Past medical history of prostate surgery - Past medical history of radiotherapy or pelvic trauma - Past medical history of acute prostatitis - Presently taking hormonal manipulation or androgen supplements. - Past medical history of cancer in the 5 previous years, excluding a non-metastatic basal cell carcinoma of the skin - Severe BPH-related urinary tract symptoms, defined by an IPSS score >18 - Serious medical illness, including any of the following: uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction, cerebrovascular event within 6 months prior to the screening visit - Contraindications for MRI exam - Extracapsular cancer extension or seminal vesicles or pelvic lymph node invasion suspected on prostate MRI - Presence of two or more clinically significant cancer foci in the inclusion biopsy exam - Presence of a clinically significant cancer with a Gleason score =8 (Grade Group =4) - Tumor largest axis >12 mm on the prostate MRI - Distance between the cancer focus and the apex <10 mm on the prostate MRI - Distance between the cancer focus and the rectum <5 mm on the prostate MRI - Patient already participating in an interventional clinical trial - Patient protected by law |
Country | Name | City | State |
---|---|---|---|
Belgium | Institut Jules Bordet | Brussels | |
France | Centre Hospitalier Universitaire de Bordeaux | Bordeaux | |
France | American Hospital of Paris | Neuilly-sur-Seine | |
France | Hôpital Cochin (Assistance Publique - Hôpitaux de Paris) | Paris | |
France | Hôpital de la Pitié-Salpêtrière (Assistance Publique - Hôpitaux de Paris) | Paris | |
France | Urologie Nantes Clinique & Institut d'Urologie - Site Atlantis | Saint-Herblain | |
France | Institut Claudius Regaud | Toulouse |
Lead Sponsor | Collaborator |
---|---|
Koelis |
Belgium, France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The proportion of patients with no evidence of cancer on targeted biopsy | The proportion of patients with no evidence of cancer on targeted biopsy at 12 months, defined by a minimum of 2 targeted core biopsies taken from the index tumor site treated with microwave ablation for focal treatment of intermediate risk prostate cancer | 12 months | |
Secondary | Proportion of radical salvage treatment | Proportion of patients undergoing radical salvage treatment of the index lesion | 12 months | |
Secondary | Time to radical salvage treatment | Time to radical salvage treatment of the index lesion | 12 months | |
Secondary | Proportion of patients with any cancer in the untreated area | Proportion of patients with any cancer in the untreated area, determined by a minimum 12 cores systematic biopsy | 12 months | |
Secondary | Proportion of patients undergoing treatment for cancer in the untreated area | Proportion of patients undergoing treatment for cancer in the untreated area and time to treatment | 12 months | |
Secondary | IPSS questionnaire | Changes in patients' reported outcome measures (PROMs) for urinary symptoms using IPSS score compared to baseline, score ranging from 0 to 35 (the higher the worse) | 7 days and 1, 6 and 12 months | |
Secondary | IIEF-5 questionnaire | Changes in patients' reported outcome measures (PROMs) for erectile function using IIEF-5 score compared to baseline, score ranging from 5 to 25 (the lower the worse) | 7 days and 1, 6 and 12 months | |
Secondary | MSHQ-EjD-SF questionnaire | Changes in patients' reported outcome measures (PROMs) for ejaculatory function and bother using MSHQ-EjD-SF score compared to baseline, score ranging from 1 to 15 (the lower the worse) for ejaculatory function and from 0 to 5 for bother/satisfaction (the higher the worse) | 7 days and 1, 6 and 12 months | |
Secondary | Urine flow | Change in urine flow, using a uroflowmeter compared to baseline | 7 days and 1, 6 and 12 months | |
Secondary | Adverse events | Number and severity of device and procedure related adverse events | 12 months | |
Secondary | Patient post-operative pain level | Average patient post-operative pain level reported on a pain numeric rating scale, with a range from 0 (no pain) to 10 (worst pain ever) | Treatment day-evaluated between 2 and 4 hours after the procedure | |
Secondary | Patient satisfaction | Patient satisfaction with the microwave ablation procedure as determined by questionnaire (no score assigned) | 1, 6 and 12 months | |
Secondary | Ease of the procedure | Ease of the procedure measured with a score chosen by the operator (1: easy, 2: moderate, 3: difficult) | Day 1 | |
Secondary | Duration of the procedure and associated variables | Duration of the procedure and associated variables | Day 1 | |
Secondary | PSA | Change in PSA measurement compared to baseline | 1, 3, 6, 9 and 12 months | |
Secondary | PSA Nadir | Time to PSA Nadir after treatment of the index lesion | 12 months | |
Secondary | Prostate volume | Change in volume of the prostate on the mpMRI compared to baseline | 7 days and 6 and 12 months | |
Secondary | Patient motivation | Characterization of patient motivation to undergo targeted microwave ablation for treatment of the index lesion, as assessed by patient questionnaire (no score assigned) | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |